On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards. As a reputable source for industry news, BioSpectrum Asia magazine recognizes the outstanding achievement and performance of leading life science companies through the annual Excellence Awards ceremony, “picking tomorrow’s winners, nudging today’s entrepreneurs to achieve greater glory and honouring yesterday’s key players who laid the foundation for success.”
On December 02, Agilex Biolabs will be felicitated with the Top Company award in a star-studded award ceremony to be held in Singapore in recognition of its strides in innovation and reputation for quality. In 2022, Agilex expanded its bioanalytical offerings to include vaccines and cell and gene therapies and built a new purpose-built GLP toxicology facility to help international biotech and pharma companies looking to place IND-enabling safety studies in Australia.
“We are grateful and honoured to be recognised amongst the stalwarts of Asian life sciences industry as we all relentlessly work towards advancing therapies that have gone on to change patients’ lives,” said Jason Valentine, CEO of Agilex Biolabs. “Our 25-year track record of bioanalytical excellence and expanded toxicology capabilities poise us as a trusted partner for global biopharmas as they turn to Australia for their nonclinical and clinical research programs”.
“We are confidant [Agilex] will lead the way in this sector in the coming years,” said Ankit Kankar, DY General Manager at BioSpectrum Asia.
Agilex Biolabs is Australia’s largest and most technologically advanced regulated bioanalytical and toxicology laboratory, providing reliable and defendable data to biotech and pharmaceutical companies worldwide in support of their drug development programs. Agilex is a proud member of the Healius network.